The predictive value of the triglyceride-glucose index for cardiovascular and cerebrovascular outcomes in patients with acute coronary syndrome underwent emergency percutaneous coronary intervention
CSTR:
Author:
Affiliation:

1.Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;2.Department of Cardiovascular Medicine, Weinan Central Hospital, Weinan, Shaanxi 714000, China)

Clc Number:

R541

  • Article
  • | |
  • Metrics
  • |
  • Reference [40]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    Aim To investigate the relationship between the triglyceride-glucose (TyG) index and major adverse cardiovascular and cerebrovascular events (MACCE) in the acute coronary syndrome(ACS) patients underwent emergency percutaneous coronary intervention (PCI) with drug-eluting stents. Methods Overall, 2 249 patients with ACS underwent emergency PCI were enrolled in this study. The patients were divided into high TyG index group and low TyG index group according to the median TyG index. The incidence of endpoint events as follows:all-cause death, non-fatal myocardial infarction(MI), non-fatal ischemia stroke, and ischemia-driven revascularization were determined and compared between two groups.Unitivariate and multivariate Cox analysis were used to evaluate the predictive value of the TyG index for MACCE. Subgroup analysis was used to evaluate the consistency of the predictive value of the TyG index for MACCE. Results Overall, 299 (13.3%) endpoint events were documented during a 66-month follow-up. Compared with the low TyG index group, the high TyG index group had a significantly higher incidence of MACCE (17.1% vs. 9.5%, P<0.001), all-cause death (6.2% vs. 3.7%, P=0.007), cardiac death (4.4% vs. 2.1%, P=0.002), non-fatal MI (1.0% vs. 0.3%, P=0.001), non-fatal ischemia stroke (2.0% vs. 1.0%, P=0.039) and ischemia-driven revascularization (7.8% vs. 4.8%, P=0.001). The multivariable Cox regression analysis further revealed that the TyG index was an independent predictor of MACCE (hazard ratio (HR)1.0,5% confidence interval (CI) 1.304~2.242,P<0.001). The results of subgroup analysis showed that the predictive effect of TyG index on MACCE still existed in different subgroups. Conclusion The TyG index might be an independent predictor of MACCE in patients with ACS underwent emergency PCI with drug-eluting stents.

    Reference
    [1] EISEN A, GIUGLIANO R P, BRAUNWALD E.Updates on acute coronary syndrome:a review.JAMA Cardiol, 6,1(6):718-730.
    [2] BENJAMIN E J, VIRANI S S, CALLAWAY C W, et al.Heart disease and stroke statistics-2018 update:a report from the American heart association.Circulation, 8,7(12):e67-e492.
    [3] JERNBERG T, HASVOLD P, HENRIKSSON M, et al.Cardiovascular risk in post-myocardial infarction patients:nationwide real world data demonstrate the importance of a long-term perspective.Eur Heart J, 5,6(19):1163-1170.
    [4] FOX K A A, CARRUTHERS K F, DUNBAR D R, et al.Underestimated and under-recognized:the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).Eur Heart J, 0,1(22):2755-2764.
    [5] ORMAZABAL V, NAIR S, ELFEKY O, et al.Association between insulin resistance and the development of cardiovascular disease.Cardiovasc Diabetol, 8,7(1):122.
    [6] DI P A, DEFRONZO R A.Insulin resistance and atherosclerosis:implications for insulin-sensitizing agents.Endocr Rev, 9,0(6):1447-1467.
    [7] MUNIYAPPA R, LEE S, CHEN H, et al.Current approaches for assessing insulin sensitivity and resistance in vivo:advantages, limitations, and appropriate usage.Am J Physiol Endocrinol Metab, 8,4(1):E15-E26.
    [8] DU T T, YUAN G, ZHANG M X, et al.Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance.Cardiovasc Diabetol, 4,3:146.
    [9] NAVARRO-GONZLEZ D, SNCHEZ-IGO L, PASTRANA-DELGADO J, et al.Triglyceride-glucose index(TyG index)in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose:the vascular-metabolic CUN cohort.Prev Med, 6,6:99-105.
    [10] WANG A X, WANG G Y, LIU Q, et al.Triglyceride-glucose index and the risk of stroke and its subtypes in the general population:an 11-year follow-up.Cardiovasc Diabetol, 1,0(1):46.
    [11] TIAN X, ZUO Y T, CHEN S H, et al.Triglyceride-glucose index is associated with the risk of myocardial infarction:an 11-year prospective study in the Kailuan cohort.Cardiovasc Diabetol, 1,0(1):19.
    [12] LUO JW, DUAN WH, YU YQ, et al.Prognostic significance of triglyceride-glucose index for adverse cardiovascular events in patients with coronary artery disease:a systematic review and Meta-analysis .Front Cardiovasc Med, 1,8:774781.
    [13] IBANEZ B, JAMES S, AGEWALL S, et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC).Eur Heart J, 8,9(2):119-177.
    [14] ROFFI M, PATRONO C, COLLET J P, et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC).Eur Heart J, 6,7(3):267-315.
    [15] American Diabetes Association.Diagnosis and classification of diabetes mellitus.Diabetes Care, 0,3 Suppl 1(Suppl 1):S62-S69.
    [16] GUERRERO-ROMERO F, SIMENTAL-MENDA L E, GONZLEZ-ORTIZ M, et al.The product of triglycerides and glucose, a simple measure of insulin sensitivity.Comparison with the euglycemic-hyperinsulinemic clamp.J Clin Endocrinol Metab, 0,5(7):3347-3351.
    [17] LEVEY A S, CORESH J, GREENE T, et al.Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.Ann Intern Med, 6,5(4):247-254.
    [18] ALFONSO F, BYRNE R A, RIVERO F, et al.Current treatment of in-stent restenosis.J Am Coll Cardiol, 4,3(24):2659-2673.
    [19] BAIGENT C, BLACKWELL L, EMBERSON J, et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a Meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet, 0,6(9753):1670-1681.
    [20] CANNON C P, BLAZING M A, GIUGLIANO R P, et al.Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med, 5,2(25):2387-2397.
    [21] SABATINE M S, GIUGLIANO R P, KEECH A C, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med, 7,6(18):1713-1722.
    [22] RIDKER P M, EVERETT B M, THUREN T, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med, 7,7(12):1119-1131.
    [23] 董亚兰, 胡德胜.动脉粥样硬化的炎症应答特征及运用.中国动脉硬化杂志, 2,0(4):304-312.DONG Y L, HU D S.Characteristics and application of inflammatory response in atherosclerosis.Chin J Arterioscler, 2,0(4):304-312.
    [24] MECHANICK J I, FARKOUH M E, NEWMAN J D, et al.Cardiometabolic-based chronic disease,adiposity and dysglycemia drivers:JACC state-of-the-art review.J Am Coll Cardiol, 0,5(5):525-538.
    [25] GAST K B, TJEERDEMA N, STIJNEN T, et al.Insulin resistance and risk of incident cardiovascular events in adults without diabetes:Meta-analysis.PLoS One, 2,7(12):e52036.
    [26] REWERS M, ZACCARO D, D'AGOSTINO R, et al.Insulin sensitivity, insulinemia, and coronary artery disease:the insulin resistance atherosclerosis study.Diabetes Care, 4,7(3):781-787.
    [27] TENENBAUM A, MOTRO M, FISMAN E Z, et al.Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.Eur Heart J, 5,6(19):2032-2038.
    [28] WU S J, LIU W, MA Q, et al.Association between insulin resistance and coronary plaque vulnerability in patients with acute coronary syndromes:insights from optical coherence tomography.Angiology, 9,0(6):539-546.
    [29] BONORA E, KIECHL S, WILLEIT J, et al.Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population:the Bruneck study.Diabetes Care, 7,0(2):318-324.
    [30] KEDHI E, KENNEDY M W, MAEHARA A, et al.Impact of TCFA on unanticipated ischemic events in medically treated diabetes mellitus:insights from the PROSPECT study.JACC Cardiovasc Imaging, 7,0(4):451-458.
    [31] SIMENTAL-MENDA L E, RODRGUEZ-MORN M, GUERRERO-ROMERO F.The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects.Metab Syndr Relat Disord, 8,6(4):299-304.
    [32] SNCHEZ-IGO L, NAVARRO-GONZLEZ D, FERNNDEZ-MONTERO A, et al.The TyG index may predict the development of cardiovascular events.Eur J Clin Invest, 6,6(2):189-197.
    [33] LAMBRINOUDAKI I, KAZANI M V, ARMENI E, et al.The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women.Heart Lung Circ, 8,7(6):716-724.
    [34] SHI W R, XING L Y, JING L, et al.Value of triglyceride-glucose index for the estimation of ischemic stroke risk:insights from a general population.Nutr Metab Cardiovasc Dis, 0,0(2):245-253.
    [35] THOMAS B.The global burden of diabetic kidney disease:time trends and gender Gaps.Curr Diab Rep, 9,9(4):18.
    [36] SUNG K C, PARK H Y, KIM M J, et al.Metabolic markers associated with insulin resistance predict type 2 diabetes in Koreans with normal blood pressure or prehypertension.Cardiovasc Diabetol, 6,5(1):47.
    [37] LAXY M, HUNGER M, STARK R, et al.The burden of diabetes mellitus in patients with coronary heart disease:a methodological approach to assess quality-adjusted life-years based on individual-level longitudinal survey data.Value Health, 5,8(8):969-976.
    [38] 杨珺.口服药物联合甘精胰岛素治疗2型糖尿病的临床疗效分析.中国实用医药, 2,7(27):165-167.YANG J.Analysis of the clinical efficacy of oral drugs combined with insulin glargine in the treatment of type 2 diabetes mellitus.Chin Prac Med, 2,7(27):165-167.
    [39] 孙峥, 王笑烨, 袁景, 等.达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究.实用肝脏病杂志, 2,5(6):796-799.SUN Z, WANG X Y, YUAN J, et al.Short-term efficacy of dapagliflozin and liraglutide combination in treatment of patients with non-alcoholic fatty liver disease and diabetes mellitus type 2.J Prac Hepatol, 2,5(6):796-799.
    [40] 徐爽, 童慧昕, 梁琳琅, 等.二甲双胍、达格列净、利拉鲁肽联合治疗新诊断超重或肥胖2型糖尿病患者临床疗效及安全性.临床军医杂志, 2,0(12):1252-1254.XU S, TONG H X, LIANG L L, et al.Clinical efficacy and safety of combined treatment of metformin, dapagliflozin and liraglutide in newly diagnosed overweight or obese patients with type 2 diabetes mellitus.Clin J Med Offic, 2,0(12):1252-1254.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

ZHANG Yong, CAI Xiang, ZHONG Zhong, NING Feifei, GUO Ning. The predictive value of the triglyceride-glucose index for cardiovascular and cerebrovascular outcomes in patients with acute coronary syndrome underwent emergency percutaneous coronary intervention[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(8):687-696.

Copy
Share
Article Metrics
  • Abstract:479
  • PDF: 988
  • HTML: 0
  • Cited by: 0
History
  • Received:December 03,2022
  • Revised:March 10,2023
  • Online: July 20,2023
Article QR Code